From new product introductions to swiped trade secrets, chipmakers have stolen the spotlight so far this week. But let’s not forget about biotech stocks, five of which are highlighted in IBD’s Screen of the Day, Big Cap Leaders, along with their semiconductor counterparts. The large-cap biotechs include Celgene (CELG), Regeneron Pharmaceuticals (REGN) and Gilead Sciences (GILD) Celgene, which has a highest-possible IBD Composite Rating of 99,
The IBD 50 is a ranking of leading stocks based on key measures such as earnings and sales growth, profit margins, return on equity and relative price performance during the past 12 months. Here’s a look at five tech-centric IBD 50 stocks with outstanding EPS growth, including Apple (AAPL) supplier Avago Technologies (AVGO): GoPro (GPRO) chip supplier Ambarella (AMBA) , which is currently ranked No. 1 on the IBD 50 list, saw earnings grow 162%
Earnings season is winding down, but there are still top stocks due to report, including drug giant Actavis (ACT), one of several drug stocks reporting earnings that day, including Intrexon (XON), Impax Laboratories (IPXL) and Juno Therapeutics (JUNO). Actavis is on the IBD 50 list of the very best stocks. Three other IBD 50 stocks — Regeneron Pharmaceuticals (REGN), Monster Beverage (MNST) and Autohome (ATHM) dished out results in the latest